ISM9077 / Insilico Medicine - LARVOL DELTA

Insilico Medicine Nominates ISM9077, Potential First-in-class Target Y Inhibitor, as Preclinical Candidate (PCC) for Ocular Diseases, Inflammatory Disorders and Aging (Insilico Medicine Press Release) - "In preclinical studies, ISM9077 demonstrated robust in vivo efficacy across ocular disease models, after both oral administration and topical eye drop delivery...In dry AMD models, ISM9077 significantly improved retinal structural integrity and visual function. On key evaluation endpoints, ISM9077 demonstrated efficacy approximately three times of currently available therapy, while simultaneously demonstrating superior histopathological improvement....Across independent uveitis models, ISM9077 reduced ocular inflammation, suppressed the release of inflammatory cytokines, and restored retinal function."

Pipeline update • Preclinical • Dry Age-related Macular Degeneration • Uveitis